SymBio PharmaceuticalsSymBio Pharmaceuticals Limited4582東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP

What does SymBio Pharmaceuticals do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

※ Operating cash flow is negative

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income-¥4.78B

Operating cash flow-¥4.58B

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow-¥4.58B

Free cash flow—

Net income-¥4.78B

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第21期(2025/01/01－2025/12/31)
ID S100XNE52026-03-24Open
EDINET (FSA Japan)
有価証券報告書－第20期(2024/01/01－2024/12/31)
ID S100VGDJ2025-03-25Open
EDINET (FSA Japan)
有価証券報告書－第19期(2023/01/01－2023/12/31)
ID S100T3FG2024-03-22Open
EDINET (FSA Japan)
訂正有価証券報告書－第18期(2022/01/01－2022/12/31)
ID S100QG6E2023-03-24Open
EDINET (FSA Japan)
有価証券報告書－第17期(令和3年1月1日－令和3年12月31日)
ID S100NPZC2022-03-29Open
EDINET (FSA Japan)
有価証券報告書－第16期(令和2年1月1日－令和2年12月31日)
ID S100L0KX2021-03-24Open

Extracted from XBRL: 40

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.